Quarterly ResultAug 5, 2026, 06:37 AM
Recursion Q2 Net Loss $131M; Genentech Options First Neuroscience Target
AI Summary
Recursion Pharmaceuticals reported a net loss of $131.0 million for Q2 2026, an improvement from the $171.9 million loss in Q2 2025, despite a decrease in total revenue to $7.7 million. The company also announced a significant milestone with Genentech advancing the first neuroscience target into an early discovery program, validating Recursion's AI-native platform. Additionally, Recursion lowered its full-year 2026 cash operating expense guidance to less than $375 million and provided updates on its clinical pipeline, including upcoming data presentations for REC-4881 and the initiation of a Phase 1/2 trial for REC-7735.
Key Highlights
- Genentech advanced the first neuroscience target into an early discovery program under their collaboration.
- Q2 2026 Net Loss was $131.0 million, an improvement from $171.9 million in Q2 2025.
- Total revenue for Q2 2026 was $7.7 million, down from $19.2 million in Q2 2025.
- Reduced 2026 cash operating expense guidance to less than $375 million from less than $390 million.
- Cash, cash equivalents, and restricted cash totaled $556.8 million as of June 30, 2026.
- REC-4881 (MEK1/2 inhibitor) Phase 2 data in FAP to be presented in November 2026.
- REC-7735 (PI3Kα H1047R inhibitor) IND cleared, with Phase 1/2 trial starting in 2H26.
Price Impact
More from RXRX